Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VERTEX PHARMACEUTICALS INC / MA Director's Dealing 2015

Apr 29, 2015

29864_dirs_2015-04-29_802a81ab-206a-4889-949d-cbd2e7681a86.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-04-27

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-04-27 Common Stock G 150 $0.00 Disposed 138120 Direct
2015-04-27 Common Stock M 18312 $53.74 Acquired 156432 Direct
2015-04-27 Common Stock M 15563 $45.11 Acquired 171995 Direct
2015-04-27 Common Stock M 17000 $77.31 Acquired 188995 Direct
2015-04-27 Common Stock S 21480 $127.49 Disposed 167515 Direct
2015-04-27 Common Stock S 12933 $128.17 Disposed 154582 Direct
2015-04-27 Common Stock S 1100 $129.30 Disposed 153482 Direct
2015-04-27 Common Stock S 11321 $130.33 Disposed 142161 Direct
2015-04-27 Common Stock S 4230 $131.27 Disposed 137931 Direct
2015-04-27 Common Stock S 6316 $132.44 Disposed 131615 Direct
2015-04-27 Common Stock S 3400 $133.34 Disposed 128215 Direct
2015-04-27 Common Stock S 700 $134.05 Disposed 127515 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-04-27 Stock Option (right to buy) $53.74 M 18312 Disposed 2022-09-03 Common Stock (18312) Direct
2015-04-27 Stock Option (right to buy) $45.11 M 15563 Disposed 2023-02-04 Common Stock (15563) Direct
2015-04-27 Stock Option (right to buy) $77.31 M 17000 Disposed 2024-02-04 Common Stock (17000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 140 Indirect

Footnotes

F1: Represents a gift made to a charitable organization.

F2: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F3: Open market sales reported on this line occurred at a weighted average price of $127.49 (range $126.88 to $127.87).

F4: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5: Open market sales reported on this line occurred at a weighted average price of $128.17 (range $127.88 to $128.82).

F6: Open market sales reported on this line occurred at a weighted average price of $129.30 (range $128.93 to $129.90).

F7: Open market sales reported on this line occurred at a weighted average price of $130.33 (range $129.94 to $130.88).

F8: Open market sales reported on this line occurred at a weighted average price of $131.27 (range $130.94 to $131.92).

F9: Open market sales reported on this line occurred at a weighted average price of $132.44 (range $131.94 to $132.91).

F10: Open market sales reported on this line occurred at a weighted average price of $133.34 (range $132.98 to $133.92).

F11: Open market sales reported on this line occurred at a weighted average price of $134.05 (range $133.99 to $134.09).

F12: The option vests in 16 quarterly installments from 09/04/2012.

F13: The option vests in 16 quarterly installments from 02/05/2013.

F14: The option vests in 16 quarterly installments from 02/05/2014.